<DOC>
	<DOCNO>NCT02290886</DOCNO>
	<brief_summary>A multicenter phase I/II Clinical trial , randomize , control placebo , triple blind evaluate safety intravenous administration 3 dos autologous mesenchymal stem cell cell adipose tissue patient Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>A Multicenter Phase I/II Clinical Trial Evaluate Safety Mesenchymal Stem Cell Patients With Amyotrophic Sclerosis Lateral</brief_title>
	<detailed_description>A multicenter phase I/II Clinical trial , randomize , control placebo , triple blind evaluate safety intravenous administration 3 dos autologous mesenchymal stem cell cell adipose tissue patient Amyotrophic Lateral Sclerosis ( ALS ) . 40 patient enrol randomized one follow 4 arm : - 10 patient control group ( placebo ) - 10 patient receive dose 1 million MSC / kg - 10 patient receive dose 2 million MSC / kg . - 10 patient receive dose 4 million MSC / kg The follow-up phase patient cell infusion/placebo 6 month . At time patient complete follow-up period ( i.e. , 6 month infusion cellular product placebo ) , blind open , patient assign control group , receive cell product secondary treatment . These patient randomize receive dos use first phase . From point , begin second period follow 6 month . In addition , 6 month MSC infusion , every patient continue open extension study 36 month assess safety MSC .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Women males 18yearold . 2 . Good understanding protocol aptitude grant inform assent . 3 . Diagnosis sporadic ALS , diagnosis certainty , say , definite probable , agreement criterion `` El Escorial '' , World Federation Neurology . 4 . Forced vital capacity least 50 % one would correspond sex , height age . 5 . More 6 less 36 month evolution disease ( begin symptom ) . 6 . Possibility obtain , least , 50gr adipose tissue . 7 . Treatment riluzole , least , month inclusion . 1 . Any concomitant disease investigator 's criterion could concern measure clinical variable trial ( hepatic , renal cardiac insufficiency , diabetes mellitus , etc ) . 2 . Previous therapy stem cell . 3 . Participation another clinical trial 3 month previous entry trial . 4 . Any disease lymphoproliferative 5 . Tracheostomy /or gastrostomy . 6 . Haemophilia , diathesis hemorrhagic anticoagulative current therapy . 7 . Hypersensitivity known bovine foetal whey gentamicin . 8 . Medical precedent infection HIV serious condition immunocompromised . 9 . Positive HBV HCV serology 10 . Levels creatinine whey &gt; 3.0 subject submit haemodialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety evaluation</keyword>
	<keyword>intravenous administration</keyword>
	<keyword>3 dos autologous MSC</keyword>
	<keyword>ALS</keyword>
</DOC>